- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05527821
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
September 1, 2022 updated by: Xiaorong Dong, Wuhan Union Hospital, China
An Exploratory Clinical Study of Short Course Radiotherapy Combined With Surufatinib and Sintilimab in the Treatment of Relapsed and Refractory Advanced Solid Tumors
An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Union Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-75 years (including 18 and 75 years), both genders;
- Unresectable malignant tumors confirmed by histology or cytology (mainly biliary tract tumors, gastric cancer, small cell lung cancer, and other tumor types were included as appropriate), which failed at least after first-line standard treatment;
- The lesions can be clearly evaluated by imaging;
- Expected survival ≥ 12 weeks;
- No serious abnormalities of blood system, heart, lung, liver, kidney function or immune deficiency;
- Laboratory tests (without blood transfusion within 14 days) shall meet the following requirements:
- If a fertile man or woman is willing to use contraception during the trial;
- Physical status score ECOG 0-1;
- Patients or their family members agreed to participate in the study and signed the informed consent form;
Exclusion Criteria:
- Previous treatment with anti-VEGF/VEGFR-targeted drugs, such as surufatinib; Or previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another stimulatory or synergistic inhibition of T-cell receptors (including but not limited to CTLA-4, OX-40, LAG-3, CD137, etc.);
- Women who are breast feeding, pregnant or preparing to become pregnant;
- Corticosteroids (dose equivalent to prednisone & GT; 10 mg/ day) or other immunosuppressive therapy;
- Active, known or suspected autoimmune diseases or before 2 years of the history of the disease (in nearly 2 years can be treated as system of vitiligo, psoriasis, hair loss, or graves disease, need only thyroid hormone replacement therapy for hypothyroidism and only need insulin replacement therapy in patients with type 1 diabetes can group);
- Allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation; Persons with HIV infection or active hepatitis b or c (active hepatitis b reference: HBV DNA≥1×104 copies /ml or ≥2000IU/ml; Active hepatitis C reference: HCV RNA≥1×103 copies /ml);
- Interstitial lung disease (including past history and current condition), such as interstitial pneumonia, pulmonary fibrosis, or evidence of ILD on baseline chest CT or MRI;
- Allergic constitution and multiple drug allergy;
- Patients judged by other investigators to be unable to tolerate chemotherapy or not suitable for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Surufatinib Combined With Sintilimab and SCRT
|
Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
5Gy*5F short course radiotherapy will be delivered
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free Survival (PFS)
Time Frame: From Baseline to primary completion date, about 24 months
|
A duration from the date of initial treatment to disease progression or death of any cause
|
From Baseline to primary completion date, about 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate (ORR)
Time Frame: From Baseline to primary completion date, about 24 months
|
The incidence of confirmed complete response or partial response
|
From Baseline to primary completion date, about 24 months
|
|
Disease Control Rate
Time Frame: From Baseline to primary completion date, about 24 months
|
The incidence of complete response, partial response and stable disease
|
From Baseline to primary completion date, about 24 months
|
|
Overall survival (OS)
Time Frame: From the time of enrollment to death caused by any reason
|
From Baseline to primary completion date, about 24 months
|
From the time of enrollment to death caused by any reason
|
|
The incidence of adverse events
Time Frame: From Baseline to primary completion date, about 24 months
|
The safety and tolerability of Surufatinib will be evaluated based on adverse events data
|
From Baseline to primary completion date, about 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 30, 2022
Primary Completion (ANTICIPATED)
September 30, 2024
Study Completion (ANTICIPATED)
September 30, 2025
Study Registration Dates
First Submitted
September 1, 2022
First Submitted That Met QC Criteria
September 1, 2022
First Posted (ACTUAL)
September 6, 2022
Study Record Updates
Last Update Posted (ACTUAL)
September 6, 2022
Last Update Submitted That Met QC Criteria
September 1, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HMPL-012-SPRING-ST101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.